Tsai Chin-Ling, Liu Baoyi, Liu Yaping, Xu Zhuojun, Lin Zhuangling, Chen Ziye, Ma Yuan, Liu Yuan, Chen Zitong, Jiang Lan, Qin Zijian, Lai Kunbei, Li Tao
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou, 510060, People's Republic of China.
Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, 510060, People's Republic of China.
Clin Ophthalmol. 2025 Jul 16;19:2363-2371. doi: 10.2147/OPTH.S522293. eCollection 2025.
To analyze past trends and project future trajectories of vitreoretinal surgery in China.
A single-institution, retrospective analysis of vitreoretinal surgeries conducted at Zhongshan ophthalmic center (ZOC), Sun Yat-sen University, from 2005 to 2022, utilizing ZOC's inpatient database. Patients hospitalized in the retinal surgery department were included. The number of surgeries was stratified by final diagnosis, and a time series forecasting model was employed to predict the number of patients undergoing vitreoretinal surgery up to and including the year 2032.
The number of patients undergoing vitreoretinal surgery increased nearly fourfold from 2005 to 2022, reaching a total of 5600 vitreoretinal surgeries in 2022. The majority of indication was given for the treatment was rhegmatogenous retinal detachment (RRD). Among the diagnosis categories, macular diseases (MD) increased by 15.61%, and diabetic retinopathy (DR) by 11.99% during the study period. Vitreoretinal surgeries are projected to increased annually, with an estimated 9231 vitreoretinal surgeries by 2032.
The demand for vitreoretinal surgery in China has grown substantially over the last decade and is anticipated to rise further. Healthcare systems must adapt to accommodate the high demand.
分析中国玻璃体视网膜手术的既往趋势并预测未来发展轨迹。
利用中山大学中山眼科中心（ZOC）的住院患者数据库，对2005年至2022年在该中心进行的玻璃体视网膜手术进行单机构回顾性分析。纳入视网膜外科住院的患者。手术数量按最终诊断进行分层，并采用时间序列预测模型预测截至2032年（包括2032年）接受玻璃体视网膜手术的患者数量。
2005年至2022年，接受玻璃体视网膜手术的患者数量增加了近四倍，2022年玻璃体视网膜手术总数达到5600例。治疗的主要适应证是孔源性视网膜脱离（RRD）。在诊断类别中，研究期间黄斑疾病（MD）增加了15.61%，糖尿病视网膜病变（DR）增加了11.99%。预计玻璃体视网膜手术数量将逐年增加，到2032年估计有9231例玻璃体视网膜手术。
在过去十年中，中国对玻璃体视网膜手术的需求大幅增长，预计还会进一步上升。医疗保健系统必须做出调整以满足这一高需求。
